Novel selective antimicrobial fusion peptides

Abstract

Antimicrobial fusion peptides include a polypeptide having at least 35 amino acids and containing the amino acid sequence GIGGALLSAG X1SALX2GLAX3G LAEHFAN, where X1, X2, and X3 independently represent lysine, glutamic acid, or glutamine, and wherein at least one of X1, X2, or X3 is independently selected from glutamic acid or glutamine, including variants with at least 97% sequence homology. Pharmaceutical compositions may include the polypeptides and may be used for treatment of bacterial infection caused by C. acnes. The polypeptides are nonhemolytic and exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, which makes them useful in pharmaceutical, healthcare, medical device, food, and personal care applications.

Dependencies are inferred from the claim text.